IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
IONIS PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$44.38+1.44 (+3.35%)
Close on Oct 19, 2026
- Market cap
- $7.34B
- P/E (TTM)
- –
- Dividend yield
- –
IONIS PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Commercial Revenue [Member] | $483.36M | $467.49M | $435.85M | $380.24M | $340.37M | $309.65M | $293.08M | $286.21M | $294.56M | $300.42M | $308.59M | $310.23M | 55.3% | +42.0% |
| Research and Development Revenue [Member] | $390.73M | $590.70M | $507.86M | $586.72M | $603.68M | $407.60M | $412.06M | $516.86M | $518.90M | $476.20M | $479.06M | $304.81M | 44.7% | -35.3% |
| Collaborative Agreement Revenue [Member] | $337.63M | $541.42M | $465.79M | $510.28M | $523.73M | $328.33M | $332.65M | $414.90M | $414.18M | $363.67M | $352.66M | $223.45M | 38.6% | -35.5% |
| Royalty Revenue [Member] | $285.69M | $279.69M | $285.53M | $287.08M | $278.20M | $272.09M | $257.31M | – | – | – | – | – | 32.7% | +2.7% |
| SPINRAZA Royalties [Member] | $207.13M | $207.98M | $212.28M | $221.93M | $223.24M | $225.65M | $216.09M | $214.27M | $224.32M | $228.59M | $240.38M | $245.73M | 23.7% | -7.2% |
| Product Sales, Net [Member] | $163.85M | $151.98M | $115.32M | $57.35M | $25.56M | $6.29M | $0 | $9.49M | $17.78M | $28.43M | $0 | $33.00M | 18.7% | +541.0% |
| WAINUA Royalties [Member] | $56.45M | $50.43M | $49.09M | $43.04M | $35.09M | $28.45M | $20.21M | $10.28M | $4.91M | $1.13M | $0 | – | 6.5% | +60.9% |
| WAINUA Joint Development Revenue [Member] | $53.10M | $49.29M | $42.08M | $76.44M | $79.95M | $79.27M | $79.42M | $101.97M | $104.72M | $112.54M | $126.40M | – | 6.1% | -33.6% |
| Other Commercial Revenue [Member] | $33.82M | $35.82M | $35.00M | $35.80M | $36.62M | $31.28M | $35.77M | $44.30M | $52.21M | $60.90M | $35.79M | $64.49M | 3.9% | -7.6% |
| Other Royalties [Member] | $22.12M | $21.28M | $24.16M | $22.12M | $19.87M | $17.99M | $21.01M | – | – | – | – | – | 2.5% | +11.3% |
| Licensing and Other Royalty Revenue [Member] | – | – | – | – | – | – | – | $26.42M | $30.73M | $33.64M | $33.30M | $31.49M | – | – |
| Eplontersen Joint Development Revenue [Member] | – | – | – | – | – | – | – | – | – | – | – | $81.35M | – | – |
By region
From the segment and revenue-disaggregation notes of Ionis Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.